Physician profile
Jamie E Ellis
NPI 1891225561
$2,801.65
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.18 · 2022: $376 · 2023: $1,838 · 2024: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.28 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $307.57 | 2022-2024 | |
| Amgen INC. | $255.56 | 2021-2024 | Prolia, Evenity, Otezla |
| Novo Nordisk INC | $227.54 | 2022-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $168.62 | 2023 | Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals LP | $162.12 | 2022-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $104.81 | 2023 | |
| Lilly USA, LLC | $86.21 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Exact Sciences Corporation | $77.20 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $68.90 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.14 | 2023-2024 | Xifaxan |
| Pfizer INC. | $59.06 | 2023-2024 | |
| Abbott Laboratories | $55.18 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $47.05 | 2023 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Aspira Women'S Health INC | $41.20 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $38.49 | 2023 | Accrufer |
| Indivior INC. | $38.09 | 2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $24.87 | 2022 | |
| Inspire Medical Systems, INC. | $24.84 | 2023 | Inspire |
| Phathom Pharmaceuticals, INC. | $23.89 | 2024 | Voquezna |
| Pear Therapeutics (US), INC. | $19.06 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.72 | 2022 | |
| Qiagen, LLC | $17.04 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.14 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.